Abstract: Albuminuria is the increased excretion of the serum protein albumin into the urine. Albuminuria is classically seen as an important diagnostic marker of declining kidney function, however, more recently albuminuria has also been implicated as a marker for cardiovascular and peripheral vascular disease indicating an important link between processes governing both cardiovascular and renal function. This review will discuss i) a common mechanism for albuminuria that accounts for albuminuria seen in hypertension and other albuminuric states and ii) possible linking factors between albuminuria, hypertension and cardiovascular disease.
INTRODUCTION
Excess albumin in the urine, or albuminuria, has been regarded for over 40 years as a principal marker for renal disease. More recently, it has become widely recognized as an independent risk indicator for cardiovascular disease mortality and morbidity for patients with diabetes mellitus and hypertension, as well as in the general population.
Clinically, the level of albuminuria is defined in three distinct ranges; normoalbuminuria that refers to albumin excretion less than 30 mg of albumin/g of creatinine, microalbuminuria that is defined as the abnormal increase in albumin excretion within the range of 30-299 mg of albumin/g of creatinine and macroalbuminuria that refers to albumin excretion greater than 300 mg of albumin/g of creatinine.
The clinically important levels of albuminuria seen in patients with hypertension/cardiovascular disease are in the microalbuminuric and low macroalbuminuric range. More drastic loss of albumin (>3g/day) may occur in kidney disease patients and preeclampsia.
Recent studies into the factors governing the manifestation of albuminuria in hypertension and diabetes have drawn important links between-I) upregulated renin-angiotensin system (RAS) and increased growth factor expression and II) disrupted albumin processing by the kidney. Interestingly, increased RAS and transforming growth factor-1 (TGF-) are also implicated in the disruption of cardiovascular function, in particular the manifestation of cardiac hypertrophy and fibrosis. The role that the RAS and growth factor expression may have on cardiovascular disease progression and their role in the manifestation of albuminuria will be the focus of this review.
MICROALBUMINURIA AND ALBUMIN PROCESS-ING BY THE KIDNEY

Albumin Degradation Pathway
It has been shown that albumin filtered by the kidney is endocytosed by proximal tubular cells, degraded into *Address correspondence to this author at the Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia 3084, Tel: +61 422 382 355; Fax: +61 3 9876 5851; E-mail: wcomper@hotmail.com peptides in lysosomes and that these peptides are exocytosed back into the tubular lumen and excreted in the urine [1] [2] [3] [4] [5] . This finding not only represents a new pathway for the renal processing of albumin but also has important ramifications for the way in which urinary albumin is quantified and for understanding a glomerular permeability-independent-mechanism by which albuminuria may occur. The albumin degradation pathway appears non-specific as various filtered proteins are processed by this pathway. The broad scope of proteins processed is consistent with previous studies (6-7) that show a potential common tubular reabsorption site for various proteins. Filtered proteins such as albumin exist in urine predominantly in peptide fragment form, in the molecular weight range <500Da [4] . Immunochemical-based assays, commonly used to assess urinary albumin excretion, have been shown not to detect fragmented albumin in urine, possibly due to the loss of conformational epitopes on the albumin molecule upon degradation.
Quantitative studies into the level of albumin derived peptide fragments excreted in the urine of normoalbuminuric humans suggest that 1-3 g of albumin derived fragments (not measured by immunoassay) are excreted per day, in combination with less than 10-30 mg day -1 of intact albumin [2, 8] (measurable by immunoassay). The kidney, therefore, plays a significant role in the catabolism of albumin. The elimination rate of albumin in humans has been measured at 0.233 g.kg body wt -1 .day -1 or around 16-17 g day -1 [9] which is approximately 16% of the circulating albumin and 7-8% of the total albumin pool. The excretion of 1-3 g of albumin derived material by the kidney [2, 8] corresponds to 6-18% of the albumin eliminated from the circulation per day.
Induction of Albuminuria via Disruption of the Degradation Pathway
Although albuminuria is thought to be derived from changes in glomerular permselectivity to albumin, recent studies have shown that the glomerular basement membrane does not offer any significant charge repulsion to albumin [3, [10] [11] [12] [13] . This would suggest that glomerular permeability is governed by size selectivity; possibly by the slit pore alone. Studies in hypertensive and diabetic rats have shown that the level of albuminuria in these states is not associated with changes in glomerular permeability (as assessed by the fractional clearance of Ficoll of equivalent hemodynamic radius to albumin) [14] . Changes in the post-glomerular handling of albumin are therefore implicated in the induction of albuminuria in hypertensive and diabetic states. It is apparent that inhibition of degradation pathway (responsible for protein fragments in the urine) yields non-nephrotic levels of albuminuria as measured by assays such as immuno-based assays that detect intact protein only. That is, albuminuria is promoted by metabolic events or signals that affect the degradation pathway, such as changes in lysosomal function and/or trafficking, thus changing the ratio of intact to fragmented albumin in diseased states, independent of glomerular capillary wall permeability [3, 8, 10, [15] [16] . This mechanism is likely to account for albuminuria at levels greater than 30 mg day -1 and less than 1-3 g day -1 observed in hypertension, diabetes, exercise, altitude proteinuria, orthostasis and tubular causes.
The Mechanism of Albuminuria in the Spontaneously Hypertensive Rat Model
The spontaneously hypertensive rat model (SHR) has been commonly used in the investigation of the effect of high blood pressure on renal function [17] [18] . SHR rats were first colonized in 1963 by Okamato and Aoki [19] by mating an outbred male Wistar Kyoto rat with spontaneous hypertension to a female Wistar Kyoto rat with slightly elevated blood pressure. The resulting SHR offspring are characterized by a systolic blood pressure of over 150 mm Hg persisting for more than one month [19] . Typically, blood pressure in the SHR gradually increases at 5-6 weeks of age to reach systolic blood pressures of 180-200 mmHg during adulthood [20] . When left untreated, these rats are prone to develop cardiac hypertrophy, cardiac failure and renal dysfunction; similar to that seen in humans.
Albuminuria associated with hypertension in the SHR rat model was measured by different assays and is shown in Fig. (1) [21] . Intact albumin excretion was measured by RIA and total albumin excretion (intact albumin plus albumin derived fragments) was measured by analysis of radiolabelled albumin in the urine following renal passage. The conventionally measured albuminuria (by radioimmunoassay) increased significantly but the total amount of albumin in the urine did not change. It was concluded that in the SHR model, hypertension related albuminuria is due to changes in the postglomerular degradation of albumin which may be affected by changes in lysosomal activity or intracellular trafficking of albumin to and from lysosomes [14, [21] [22] .
Factors Affecting the Renal Processing of AlbuminPotential Role of RAS and TGF-Production
A variety of studies over the past decades have implicated RAS and growth factor production in the manifestation of kidney disease onset and progression. Fig. ( 2) outlines the association of the RAS and TGF-pathways in the kidney demonstrating that both the RAS and TGF-pathways are intimately linked. TGF-and/or angiotensin II (AngII) production may be regulated by high glucose [23] [24] , blood pressure [25] [26] [27] [28] [29] [30] , glycated albumin [31] , glucose induced gremlin production [32] (which is a bone morphogenic protein (BMP7) antagonist) [33] and BMP7 [34] which decreases TGF-production ( Fig. 2) . Further AngII may also directly stimulate TGF-production [35] .
TGF-is a prosclerotic hormone that plays an important role in the production of fibronectin and collagen IV, important in the induction of fibrosis [36] . The association of renal hypertrophy and inhibition of lysosomal enzymes is well established [37] [38] [39] [40] [41] and TGF-pro-sclerotic function is not limited to the promotion of collagen production but extends to an inhibitory effect on lysosomal function. Schenk et al. [42] demonstrated that TGF-suppresses the activity of lysosomal enzymes, particularly lysosomal cysteine proteinases (cathepsins), which are primarily responsible for tissue turnover in the kidney [42] . Fig. (1) . The relationship of different forms of excreted albumin in albuminuric spontaneously hypertensive rats (SHR) (blood pressure 223+/-11 mmHg) as compared to control rats (WKY) (blood pressure 150+/-11 mmHg). When albumin is measured by radioimmunoassay (RIA)(that measures intact native albumin filled bars) an increase in albumin fractional clearance is observed for hypertensive rats as compared to normotensive controls. On the other hand when all albumin derived material is measured by radioactivity (unfilled bars) there is no change in fractional clearance in hypertensive rats #* P<0.01 for comparison of age-mached WKY vs SHR (Reprinted with permission from Russo et al. [21] ).
It has been postulated that this decrease in lysosomal function by TGF-may also affect the degradation pathway for albumin. Studies in SHR rats with and without streptozotocin (STZ) induced Type 1 diabetes demonstrated a distinct correlation between albuminuria induction and lysosomal activity changes [14, 21, 22, 43] . Studies by Gekle et al. [44] have further demonstrated in opossum kidney (OK) kidney cells, that the addition of TGF-can disrupt both albumin uptake and degradation. This supports the theory that increased TGF-in diabetes and hypertension may be involved in the disruption of albumin processing by the degradation pathway giving rise to increased intact albumin excretion better known as 'albuminuria'.
Albuminuria is also thought to be directly promoted by AngII. Studies using the ex vivo isolated perfused kidney and in vivo rat studies demonstrated that AngII directly influences albumin processing by the kidney and can induce high levels of albuminuria independently of changes in glomerular permeability [45] . Increased AngII has been shown to correlate with increased extracellular matrix deposition and has been directly implicated in the development of renal hypertrophy and fibrosis [46] [47] [48] [49] [50] [51] [52] . This disruption may occur via AngII induced upregulation of TGF-or via a TGFindependent pathway directly involving AngII binding to the AT 1 receptor.
The Effect of RAS and TGF-Blocking Agents on Urinary Albumin Excretion
Further supporting evidence for the possible role of RAS and TGF-in the induction of albuminuria has been revealed by the use of RAS and TGF-effecting agents. RAS effecting drugs have been shown to be efficacious in the treatment of albuminuria in both hypertensive and normotensive humans and rats [53] [54] [55] . This would suggest that RAS induced albuminuria may occur independently of the hemodynamic effects of the RAS. TGF-reducing interventions including the use of TGF-blocking antibodies [56] [57] and TGFbinding small molecules [58] , BMP7 treatment (which downregulates TGF-production and is reduced in diabetes) [34] and TGF-type 2 receptor heterozygous animals [59] , have all been shown to reduce albuminuria. This amelioration may be directly related to TGF-induced disruption of albumin processing (14, 21, 22, 43) .
CLINICAL EPIDEMIOLOGICAL STUDIES
Albuminuria, in particular microalbuminuria, commonly occurs in hypertensive patients. Microalbuminuria occurs in 5-40% of patients with essential hypertension [60] [61] [62] [63] [64] and tends to correlate with the level of systolic blood pressure, particularly with 24 hour ambulatory blood pressure [63, 65] . The prevalence of microalbuminuria in hypertensive patients increases with age and duration of hypertension [60] . Patients with essential hypertension and microalbuminuria also have increased carotid artery wall thickness [66] , left ventricular hypertrophy, non-fatal myocardial infarcts, and peripheral vascular disease [61] . In hypertension, most ischemic heart disease events occur in the subset of patients who have microalbuminuria [67] .
In a cross-sectional study of 11,343 non-diabetic hypertensive patients with a mean age of 57 years, Agrawal et al. [68] established the role of microalbuminuria as an indicator of cardiovascular risk in essential hypertension. Individuals with microalbuminuria demonstrated a significantly higher prevalence of coronary artery disease (31% versus 22.4%), left ventricular hypertrophy (24% versus 13.8%), stroke (5.8% versus 4.2%), myocardial infarction (7% versus 4%), and peripheral vascular disease (7.3% versus 4.9%) compared with normoalbuminuric patients. The prevalence of microalbuminuria in this population was over 30%. The risk of premature cardiovascular death is predicted to be four times higher in patients with microalbuminuria than in normoalbuminuric patients [69] . Numerous studies have also reported that even below the traditional microalbuminuria threshold, albuminuria level is predictive of adverse renal and cardiovascular events [70] [71] [72] [73] . Fig. (2) . Schematic diagram demonstrating that RAS and TGF-production pathways are intimately linked. The production of AngII and TGF-may be increased in hypertension and diabetes by increased glucose, glycated albumin and increased stretch forces induced by hypertension. Interestingly, glucose induced TGF-production may also be regulated by Gremlin and BMP7 production. BMP7 is a natural inhibitor of TGF-and is down-regulated by Gremlin in the presence of high glucose. Increased TGF-and AngII in hypertension and diabetes can lead to increased Collagen IV and Fibronectin production as well as decreased lysosomal activity promoting hypertrophy in the kidney and heart and albuminuria in the kidney.
In an early study conducted by Mogensen [74] , microalbuminuria was more strongly predictive of all-cause and cardiovascular mortality in hypertensive patients than in normotensives. Microalbuminuria increased the relative risk of all-cause mortality by 5-fold in hypertensive patients, after adjusting for age, sex, impaired glucose tolerance and diabetes.
Hypertensive patients with low levels of albuminuria (even in the normal range) in both the LIFE and AASK studies showed an increased cardiovascular risk with each increase in urinary albumin levels [72, 75] . Using the LIFE study group it was also recently established that a reduction in albuminuria during anti-hypertensive treatment translates to a reduction in cardiovascular risk [76] indicating a link between factors leading to albuminuria and cardiovascular disease.
Disturbingly, cardiovascular disease also accounts for up to 80% of deaths in the diabetic population [77] . Microalbuminuria occurs in 10-42% of patients with Type 1 and Type 2 diabetes and is associated with disease duration [78] [79] . According to prospective cohort studies, microabuminuria independently predicts cardiovascular endpoints in Type 1 diabetes. Approximately 10-20% of Type 1 diabetic patients have been reported to develop microalbuminuria when followed for approximately 5-10 years. In the Natural History of Microalbuminuria Study, a prospective cohort of patients with Type 1 diabetes attending the Joslin Clinic Diabetes Centre was studied. Normoalbuminuric patients were followed for 4 years and 11% developed microalbuminuria [80] . A 10-year observational follow-up study of 939 Type 1 diabetic adults at the Steno Diabetes Centre showed that microalbuminuria predicted cardiovascular mortality independently of other cardiovascular risk factors, with a relative risk of 1.45 [81] .
More recently, attention has been directed towards investigating the association between microalbuminuria and cardiovascular events in Type 2 diabetic patients. Patients with Type 2 diabetes and microalbuminuria have approximately a 4-fold increased risk of premature cardiovascular death compared to normoalbuminuric Type 2 diabetic patients and are more likely to die from cardiovascular disease before progressing to end-stage renal disease [69] . A meta-analysis that investigated the association of microalbuminuria and mortality in Type 2 diabetes found a strong association between microalbuminuria and total mortality or cardiovascular morbidity and mortality [82] . Microalbuminuria doubled cardiovascular morbidity and mortality and more than doubled the all-cause mortality rate. This association was retained even after adjustment for other cardiovascular risk factors.
In a prospective cohort study of 840 Type 2 diabetic patients from the Wisconsin Epidemiological Study of Diabetic Retinopathy, 24.8% had microalbuminuria and 20.5% had massive proteinuria [83] . During the 12-year follow-up, those with microalbuminuria and proteinuria had significantly higher risks of cardiovascular and all-cause mortality. The relative risk of cardiovascular death was 1.84 for those with microalbuminuria and 2.61 for those with proteinuria. Further adjustment for cardiovascular and diabetes risk factors including age, sex, glycemic control, insulin use, alcohol intake, physical activity, use of anti-hypertensive drug therapy and history of cardiovascular disease did not change these relations.
Among the more than 9,000 subjects at high risk in the HOPE study, 33% of patients with diabetes also had microalbuminuria, in comparison to 15% of those without diabetes. Microalbuminuria increased the adjusted relative risk of major cardiovascular events (myocardial infarction, stroke or cardiovascular death) by 1.83-fold, all-cause mortality by 2.09-fold and hospitalisation for congestive heart failure by 3.23-fold in these participants. The HOPE trial also demonstrates that cardiovascular risk extends well into the normal range of urinary albumin excretion rate [70, 84] .
The prevalence of microalbuminuria in the general, nondiabetic population is reported to be between 5% and 10% [85] [86] . Large-scale, prospective studies in such general populations have found an association between microalbuminuria and increased risk for all-cause mortality [87] . Borch-Johnsen et al. [88] reported that in 2,085 Danish subjects, the relative risk of ischemic heart disease associated with microalbuminuria was 2.3. Microalbuminuria increased the risk associated with other established atherosclerotic risk factors, as well as being an independent predictor of cardiovascular disease.
In the PREVEND study which was conducted in the general population of Groningen and involved more than 40,000 participants, urinary albumin excretion predicted cardiovascular morbidity and mortality in a continuous fashion, irrespective of other risk markers [71, 89] . A 2-fold increase in urinary albumin concentration was associated with a 29% increase in cardiovascular death and a 12% increase in noncardiovascular death [71] . A greater degree of risk was observed in the HUNT study conducted in Norway [90] . The presence of microalbuminuria was associated with a 2-fold increased risk of all-cause mortality in 2,089 non-diabetic non-hypertensive individuals. In the larger EPIC-Norfolk study which recruited 20,911 participants, microalbuminuria was associated with a 50% independent increased relative risk of all-cause mortality and more than a doubling in the risk of cardiovascular disease mortality [91] .
MECHANISTIC RELATIONSHIP OF MICROALBU-MINURIA AND CARDIOVASCULAR DISEASE
Our research into albumin handling by the kidney has enabled us to postulate a plausible relationship between microalbuminuria and cardiovascular disease summarized in Fig. (3) . In the same way TGF-can upregulate collagen and fibronectin production, it can also reduce lysosomal cathepsin activity in the kidney, leading to fibrosis and albuminuria. TGF-can also have similar effects on the induction of hypertrophy and fibrosis in the cardiovascular system. The increased circulating levels of AngII and TGF-in hypertension may influence post-glomerular albuminuria induction, suggesting that TGF-may be a key factor in the induction of albuminuria in some cardiovascular disease states.
TGF-Production in CVD
TGF-and the RAS may modulate cardiac function by binding to their respective receptors expressed in the heart and vasculature. This promotes cardiac remodelling which is critically involved in the pathogenesis of cardiac hypertro-phy and fibrosis [92] . AngII indirectly stimulates cardiac hypertrophy, including the proliferation of cardiac fibroblasts, phenotypic conversion of fibroblasts to myofibroblasts and extracellular matrix deposition via the induction of TGF-. Increased TGF-expression has been observed during cardiac hypertrophy and fibrosis in humans and animal models. Increased TGF-mRNA was reported in the left ventricular myocardium of patients with isolated valvular aortic stenosis and left ventricular systolic dysfunction [93] , idiopathic hypertrophic cardiomyopathy [94] [95] and dilated cardiomyopathy [96] as well as in experimental models of myocardial infarction [97] [98] [99] , progressive coronary artery occlusion [100] , and pressure overload-induced hypertrophy [101] .
Direct evidence of this causal relationship comes from TGF-1 -deficient mice [102] . TGF-1 -/-/Rag1 -/-mice (which were created to overcome the lethal phenotype of TGF-1 -/-mice which is due to a multifocal autoimmune-like inflammatory disease [103] ) subjected to chronic subpressor doses of AngII showed no significant change in left ventricular mass or deterioration in systolic function. In comparison, AngII-treated wild-type mice show a greater than 20% increase in left ventricular mass, impaired cardiac function and elevated atrial natriuretic factor (a pathological hypertrophyassociated protein) expression. This effect is independent of endogenously activated RAS or the hemodynamic effects of AngII and suggests that TGF-plays an important role in cardiac hypertrophy perhaps down stream of AngII. Further, the development of cardiac fibrosis has also been shown to be significantly reduced in a heterozygous TGF-1 +/--deficient mouse model [104] .
Similar to the kidney, associations between decreased lysosomal enzyme (cysteine proteinases) activity and cardiac hypertrophy have been established [105] [106] . ACE inhibitors and AT 1 antagonists have been demonstrated to restore lysosomal enzyme activity [22, [107] [108] , and successfully prevent or reverse cardiac hypertrophy and fibrosis in humans and animal models [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] . Direct antagonism of TGF-via administration of neutralizing anti-TGF-1 antibodies or proteoglycans that bind TGF-has also proven effective in preventing fibroblast activation and fibrosis of the kidney and heart [124] [125] [126] . Further the use of the TGFinhibiting small molecule, Tranilast, has also been shown to reduce hypertrophy in both the heart and the kidney [127] [128] .
Taken together, these interrelationships provide a rationale with which to understand how microalbuminuria may be directly related to cardiovascular disease. Whilst local or systemic levels of growth factors can cause microalbuminuria by preventing the lysosomal degradation of glomerularfiltered albumin in the kidney, their upregulation can also cause inhibition of lysosomal enzymes present in the heart, leading to hypertrophy and fibrosis.
Other Factors Affecting Albuminuria
Microalbuminuria associated with cardiovascular disease, peripheral vascular disease and microvascular damage has been widely thought of as a result of endothelial dysfunction. Changes in endothelial cell properties lining the blood capillary is thought to increase albumin leakage into the underlying interstitium. While correlations of changes in endothelial cell states (as measured by circulating von Willebrand Factor antigen, a glycoprotein secreted in greater amounts when the vascular endothelium is damaged) to microalbuminuria have been made [129] [130] , there has been little or no definitive evidence that microalbuminuria is directly the result of damaged endothelium in the glomerulus or associated with excessive leakage of albumin in non-renal beds. Stehouwer [131] concludes that while there is a close relationship between endothelial function and microalbuminuria he cannot distinguish, at the present time, whether there is a direct relationship or whether endothelial function promotes factors that affect the generation of microalbuminuria in nonendothelial cell regions. Fig. (3) . The possible relationship of factors affecting albuminuria and those affecting cardiovascular disease. The arrows indicate how modulation of local/systemic cytokines may affect biochemical events in the kidney and heart (Reprinted with the permission from Comper et al. [134] ).
Other studies have suggested that in microalbuminuric states there is no change in glomerular permeability i.e. proximal tubule cells no charge selectivity and no large pores in the glomerular capillary wall. Rather, changes in the glomerular capillary wall such as the removal of heparan sulfate is thought to promote the release of cytokines and inflammatory factors [132] [133] that may affect cells involved in albumin processing i.e. proximal tubule cells.
CONCLUSION
Albuminuria in hypertension represents an important diagnostic marker for the progression of cardiovascular disease. Here we have described the common affects of RAS and TGF-in the induction of albuminuria and cardiac hypertrophy. TGF-induced by AngII dependent and independent pathways can affect collagen and fibronectin production in both the kidney and the heart. Commonly TGFmay also reduce lysosomal activity leading to increased fibrosis in the kidney and the heart as well as disruption of the renal degradation pathway for albumin leading to albuminuria.
